Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2009 (2009), Article ID 187426, 5 pages
http://dx.doi.org/10.1155/2009/187426
Research Article

Meso Scale Discovery and Luminex Comparative Analysis of Calbindin D28K

Molecular Toxicology, Safety Assessment, AstraZeneca R&D Södertälje, 151 85 Södertälje, Sweden

Received 6 May 2009; Accepted 23 July 2009

Academic Editor: Colin Cooper

Copyright © 2009 Samer Sourial et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. U. Niemann and N. J. Serkova, “Biochemical mechanisms of nephrotoxicity: application for metabolomics,” Expert Opinion on Drug Metabolism and Toxicology, vol. 3, no. 4, pp. 527–544, 2007. View at Publisher · View at Google Scholar
  2. K. Sooy, J. Kohut, and S. Christakos, “The role of calbindin and 1,25dihydroxyvitamin D3 in the kidney,” Current Opinion in Nephrology and Hypertension, vol. 9, no. 4, pp. 341–347, 2000. View at Publisher · View at Google Scholar
  3. J. Roth, D. Brown, A. W. Norman, and L. Orci, “Localization of the vitamin D-dependent calcium-binding protein in mammalian kidney,” American Journal of Physiology, vol. 12, no. 3, pp. F243–F252, 1982. View at Google Scholar
  4. G. R. Betton, K. Kenne, R. Somers, and A. Marr, “Protein biomarkers of nephrotoxicity; a review amd findings with cyclosporin A, a signal transduction kinase inhibitor and N-phenylanthranilic acid,” Cancer Biomarkers, vol. 1, no. 1, pp. 59–67, 2005. View at Google Scholar
  5. M. Takashi, Y. Zhu, K. Miyake, and K. Kato, “Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy,” Urologia Internationalis, vol. 56, no. 3, pp. 174–179, 1996. View at Google Scholar
  6. S. Hasegawa, K. Kato, M. Takashi et al., “Increased levels of calbindin-D in serum and urine from patients treated by extracorporeal shock wave lithotripsy,” The Journal of Urology, vol. 149, no. 6, pp. 1414–1418, 1993. View at Google Scholar
  7. S. S. Khan, M. S. Smith, D. Reda, A. F. Suffredini, and J. P. McCoy Jr., “Mulitplex based array assays for detecting of soluble cytokines: comparison of sensitivity and quantative values among kits from multiple manufacturers,” Cytometry Part B, vol. 61, no. 1, pp. 35–39, 2004. View at Google Scholar
  8. F. Chowdhury, A. Williams, and P. Johnson, “Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling,” Journal of Immunological Methods, vol. 340, no. 1, pp. 55–64, 2009. View at Publisher · View at Google Scholar
  9. G. Toedter, K. Hayden, C. Wagner, and C. Brodmerkel, “Simultaneous detection of eight analytes in human serum by two commercially avaliable platforms for multiplex cytokine analysis,” Clinical and Vaccine Immunology, vol. 15, no. 1, pp. 42–48, 2008. View at Google Scholar
  10. M. Y. Liu, A. M. Xydakis, R. C. Hoogeveen et al., “Mulitplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system,” Clinical Chemistry, vol. 51, no. 7, pp. 1102–1109, 2005. View at Google Scholar
  11. G. E. Lash, P. J. Scaife, B. A. Innes et al., “Comparison of three multiplex cytokine analysis systems: Luminex, SearchLightTM and FAST Quant®,” Journal of Immunological Methods, vol. 309, no. 1-2, pp. 205–208, 2006. View at Publisher · View at Google Scholar
  12. Y. Zhu, M. Takashi, K. Miyake, and K. Kato, “Sensitive enzyme immunoassay for human 28 kDa calbinin-D,” Clinica Chimica Acta, vol. 201, no. 3, pp. 183–192, 1991. View at Publisher · View at Google Scholar